Alexion Pharmaceuticals

Alexion Pharmaceuticals is an American pharmaceutical company best known for its development of Soliris, a treatment for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). The company was founded in 1992 by Leonard Bell and is headquartered in Boston, Massachusetts.

History

Alexion Pharmaceuticals was founded in 1992 by Leonard Bell, a physician and scientist. The company initially focused on the development of monoclonal antibodies for the treatment of autoimmune diseases and cancer. In 2007, Alexion received approval from the Food and Drug Administration (FDA) for Soliris, a treatment for PNH, a rare and life-threatening blood disorder. Soliris was later approved for the treatment of aHUS, another rare and life-threatening disease.

Products

Alexion's flagship product is Soliris (eculizumab), a monoclonal antibody that inhibits the activation of the complement system, a part of the immune system that can cause damage to cells and tissues. Soliris is used for the treatment of PNH and aHUS. In addition to Soliris, Alexion has developed several other products, including Ultomiris (ravulizumab), a long-acting complement inhibitor, and Strensiq (asfotase alfa), a treatment for hypophosphatasia.

Research and Development

Alexion's research and development efforts are focused on the discovery and development of therapies for the treatment of rare diseases. The company's pipeline includes potential treatments for neuromyelitis optica spectrum disorder, Wilson's disease, and amyotrophic lateral sclerosis (ALS), among others.

Acquisitions

Over the years, Alexion has acquired several companies to expand its product portfolio and research capabilities. These include Synageva BioPharma, a company focused on the development of therapies for rare diseases, and Achillion Pharmaceuticals, a company developing complement inhibitors.

Controversies

Alexion has faced several controversies, including allegations of unethical sales practices related to Soliris. In 2017, the company agreed to pay $21 million to settle charges that it had violated the Foreign Corrupt Practices Act.

See Also

• List of pharmaceutical companies
• Rare diseases
• Monoclonal antibodies